As the panelists conclude their discussion about systemic lupus erythematosus (SLE) and hemophilia, they share their perspectives about the Affordable Care Act and its potential.

Patrick F. Fogarty, MD, Hugh Fatodu, RPh, MBA, and Maria Lopes, MD, MS, raise concerns about the affordability of healthcare.

Dr Fogarty hopes that despite high treatment costs, patients with hemophilia will have access to necessary drugs and specialty hemophilia treatment centers to receive the care that they require.

Mr Fatodu discusses the need for transparency when pharmaceutical companies review orphan drug prices and explains that the cost of a drug needs to be relative to its value.

Dr Lopes believes that professionals need to work collectively to define a product’s value and determine ways to minimize overall product waste.

Michelle Petri, MD, MPH, recognizes the issues that healthcare professionals face when treating patients with SLE and explains the importance for individualized therapy.

Episode 19 - The Future of SLE and Hemophilia

During this segment, the panelists conclude their discussion about systemic lupus erythematosus and hemophilia. They share their perspectives about the Affordable Care Act and consider how it will impact the future of each disease.
Published Online: January 02, 2014
As the panelists conclude their discussion about systemic lupus erythematosus (SLE) and hemophilia, they share their perspectives about the Affordable Care Act and its potential.

Patrick F. Fogarty, MD, Hugh Fatodu, RPh, MBA, and Maria Lopes, MD, MS, raise concerns about the affordability of healthcare.

Dr Fogarty hopes that despite high treatment costs, patients with hemophilia will have access to necessary drugs and specialty hemophilia treatment centers to receive the care that they require.

Mr Fatodu discusses the need for transparency when pharmaceutical companies review orphan drug prices and explains that the cost of a drug needs to be relative to its value.

Dr Lopes believes that professionals need to work collectively to define a product’s value and determine ways to minimize overall product waste.

Michelle Petri, MD, MPH, recognizes the issues that healthcare professionals face when treating patients with SLE and explains the importance for individualized therapy.

View More From This Discussion
Episode 1 Episode 1 - Recognizing Rare Diseases in the United States
Episode 2 Episode 2 - How Advocacy and Policy Intertwine
Episode 3 Episode 3 - The Far-Reaching Burden of Rare Diseases
Episode 4 Episode 4 - A Clinical Overview of Hemophilia
Episode 5 Episode 5 - Current Therapeutic Strategies for Hemophilia
Episode 6 Episode 6 - Addressing the Gaps in Care for Hemophilia Patients
Episode 7 Episode 7 - Minimizing the Burden of SLE
Episode 8 Episode 8 - Long-Acting Agents and Considerations
Episode 9 Episode 9 - The Future Landscape for the Treatment of Hemophilia
Episode 10 Episode 10 - Treating Mild and Severe Hemophilia
Episode 11 Episode 11 - Minimizing the Burden of SLE
Episode 12 Episode 12 - Recognizing the Strengths and Weaknesses of Current Clinical Practice Guidelines
Episode 13 Episode 13 - Challenges of Measuring the Outcomes of SLE
Episode 14 Episode 14 - Unmet Needs for Treatment of SLE
Episode 15 Episode 15 - SLE: Expectations As the Drug Market Evolves
Episode 16 Episode 16 - Factors Hindering Care for SLE Patients
Episode 17 Episode 17 - Future Outlook on the Orphan Drug Market
Episode 18 Episode 18 - The Role of Specialty Pharmacies in Rare Diseases
Episode 19 Episode 19 - The Future of SLE and Hemophilia
right-arrow
Related Articles

More on AJMC.COM

$vacMongoViewPlus$